ATTO

Conviction 0HealthcareScan · Fri, Oct 2, 2026

Attovia Therapeutics, Inc. (ATTO) closed at $17.11 (-3.82%) on Oct 2, 2026. RSI(14) 35, -33.0% from its 52-week high, -21.9% year to date. Sector: Healthcare · Biotechnology.

ATTO$17.11-3.82%

ResistanceSupportVol 14Insider buyInsider sell

Vol MA14 520.82K

Aug 5Aug 17Aug 27Sep 10Sep 22Oct 2

Attovia Therapeutics, Inc.Biotechnology

Price17.11

Change-3.82%

Gap-0.22%

Rel volume0.67×

Avg volume435.86K

Avg $ vol8.82M

SMA 2020.86

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 23.54

RSI (14)35

MACD hist-0.49

MACD cross—

Stoch %K / %D6 / 8

ADX (14)17

+DI / −DI14 / 21

RSI divergence—

MACD divergence—

ATR %12.02%

ADR %10.79%

52w high25.55

52w low17.11

From 52w high-33.03%

Above 52w low+0.00%

New 52w highNo

SqueezeOff

Bollinger width51.85%

%B0.15

Donchian pos4.31%

Donchian high28.00

Donchian low16.62

AVWAP (52w high)20.40

vs AVWAP high-16.15%

AVWAP (52w low)20.59

vs AVWAP low-16.92%

OBV trendDown

Chaikin MF (20)-0.38

Today vs 20d0.67×

Avg vol (14d)520.82K

Avg vol (20d)435.86K

Avg $ vol (20d)8.82M

Market cap781.09M

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank11.2

1 week-3.77%

1 month-26.03%

3 months—

6 months—

1 year—

YTD-21.87%

P/E—

P/B-5.37

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current9.39

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target39.75

Target upside132.32%

Analyst ratingBuy

Institutional—

Ent. value748.26M

Revenue450K

Net income-20.69M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float26.26M

Float %57.5%

Short interest648.54K

Days to cover3.1d

Short volume59.5%

Squeeze score33 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$4.88

Last surprise—

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank11.2 / 100

Group rank14 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance26.73

Support16.39

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ATTO

All disclosures →

No recent disclosed trades by Congress in ATTO. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ATTO · open-market 2 buys

Insider	Side	Shares	Value	Traded	Filed
GOLDMAN SACHS GROUP INC Insider · Common Stock · 2026-08-06	Buy	500K	$8.5M	2026-08-06	2026-08-28
GOLDMAN SACHS GROUP INC Insider · Series B Preferred Stock · 2026-08-06	Convert	18.18M	—	2026-08-06	2026-08-28
WALSH COLIN Director · Common Stock · 2026-08-06	Convert	1.96M	—	2026-08-06	2026-08-28
WALSH COLIN Director · Common Stock · 2026-08-06	Convert	478.5K	—	2026-08-06	2026-08-28
WALSH COLIN Director · Common Stock · 2026-08-06	Buy	500K	$8.5M	2026-08-06	2026-08-28
WALSH COLIN Director · Series B Preferred Stock · 2026-08-06	Convert	18.18M	—	2026-08-06	2026-08-28
WALSH COLIN Director · Series C Preferred Stock · 2026-08-06	Convert	4.45M	—	2026-08-06	2026-08-28
GOLDMAN SACHS GROUP INC Insider · Series C Preferred Stock · 2026-08-06	Convert	4.45M	—	2026-08-06	2026-08-28
GOLDMAN SACHS GROUP INC Insider · Common Stock · 2026-08-06	Convert	1.96M	—	2026-08-06	2026-08-28
GOLDMAN SACHS GROUP INC Insider · Common Stock · 2026-08-06	Convert	478.5K	—	2026-08-06	2026-08-28

SEC filings

EDGAR filings in ATTO · 9 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.

ATTO

Recent news

Get daily signals & real-time alerts.